BMX-IN-4
BMX-IN-4 is a covalent BMX kinase inhibitor with an IC50 of 1.78 nM and a Ki of 0.158 μM. BMX-IN-4 forms a covalent bond with BMX kinase. BMX-IN-4 is applicable to the research of hepatocellular carcinoma.
For research use only. We do not sell to patients.
- CAS No.: 3132799-96-0
- Formula: C21H15ClN4O2S
- Molecular Weight:422.89
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
BMX-IN-4 (Compound 11i) potently inhibits recombinant BMX with an IC50 of 1.78 nM; it exhibits 2.3-fold selectivity over recombinant BTK, and its activity is dependent on a covalent warhead[1].
BMX-IN-4 achieves selective cellular target binding to BMX but not BTK in HEK293T cells, with an EC50 of 0.098 μM against BMX and a selectivity window of 20.6-fold[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3132799-96-0
-
Molecular Weight 422.89
-
Formula C21H15ClN4O2S
-
SMILES
O=C(NC1=CN=C(C2=C1)NC=C2C3=CC=CC(NC(C=C)=O)=C3)C4=CC=C(S4)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BMX-IN-4 Related Classifications
HY-187351 Related Classifications
Powered by Bioz